Report Overview

The Oncology Drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

In Kenya, Cancer is the third leading cause of death after infectious diseases and cardiovascular diseases. The annual incidence of cancer in Kenya is about 28 000 new cases with an annual mortality of 22 000 cases, that is, 78.5% of the victims do not survive. The five most common cancer in Kenya are Breast, Cervical, Prostate, Oesophagus and Colorectal Cancer. The leading cause of deaths among females is Cervical cancer followed by Breast cancer and among males is Prostate cancer followed by Oesophagus cancer. The rising incidence of cancer in Kenya may be attributed to increase in the ageing population, adoption of unhealth lifestyles, tobacco and alcohol consumption and physical inactivity. Some chronic infections are risk factors for cancer, in low- and middle-income countries. These carcinogenic infections are caused by Helicobacter pylori, Human papillomavirus (HPV), Hepatitis B virus, Hepatitis C virus, and Epstein-Barr virus.



Market Drivers

The market is majorly driven by the rising incidence of cancer cases in Kenya, which is the primary reason for growth in the Oncology Drug market. As the burden of cancer cases increase in the young population due to increase in the risk factors, need for therapies like Immunotherapy and Targeted Therapy emerge.

Increasing levels of awareness related to early diagnosis and screening of breast and cervical cancers in females and available therapies are leading to a high growth of Oncology Drug.

Increase and an improvement in the diagnostic capabilities in the country will propel growth in the oncology Drug market in Kenya in the forecasted period.

However, the side effects caused by Chemotherapy and Immunotherapy are restraining market growth. Some of the products are withdrawn from the market due to serious side effects. Other restraints of market growth include high cost of treatment and oncology Drug. The National Hospital Insurance Fund (NHIF) provides only 25,000 Kenyan Shillings per patient towards cancer care.